Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01694966 · ClinicalTrials.gov registry record · Phase 3
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
A Phase 3 study, sponsored by Cosmo Technologies.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,249
- Enrollment target
NCT01694966: Completed Phase 3 study, sponsored by Cosmo Technologies.
NCT01694966 is a Phase 3 study that has completed, run by Cosmo Technologies. The registered enrollment target is 1,249 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (62% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01694966, a Phase 3 study, has completed, sponsored by Cosmo Technologies.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,249 participants
- Enrollment target
Study Summary
Evaluation of the histologically proven adenoma and carcinoma detection rate in patients undergoing a full colonoscopy with and without mucosal contrast enhancement, obtained with 200 mg of Methylene Blue MMX® tablets.
Primary Outcome
Adenoma Detection Rate
Interventions
- DRUG Placebo
- DRUG Methylene Blue MMX®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,249 participants |
| Start Date | 2013-09 |
| Est. Completion | 2016-10 |
| Phase | Phase 3 |
What the finished NCT01694966 record still lists
NCT01694966 is an interventional study that assigns participants to a tested intervention. Its 1,249 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (62% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01694966 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01694966 about?
NCT01694966 is a clinical study titled "The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy". Evaluation of the histologically proven adenoma and carcinoma detection rate in patients undergoing a full colonoscopy with and without mucosal contrast enhancement, obtained with 200 mg of Methylene Blue MMX® tablets.
What is the current status of trial NCT01694966?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,249 participants. The study started on 2013-09. Estimated completion is 2016-10.
What interventions are being tested in trial NCT01694966?
The interventions under investigation include: Placebo (DRUG), Methylene Blue MMX® (DRUG).
Who is sponsoring clinical trial NCT01694966?
This trial is sponsored by Cosmo Technologies, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01694966's enrollment target sits among peer trials
1,249 210th of 2000 higher than 1,791 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02743858 · 1,250 participants
Lymphedema Surveillance Study
- NCT04670874 · 1,250 participants
Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29
- NCT04807868 · 1,250 participants
AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)
- NCT05995821 · 1,250 participants
Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia